1. Sokumbi O, Drage L, Peters, M. Clinical and histopathologic review of Schnitzler syndrome: The Mayo Clinic experience (1972-2011). J Am Acad Dermatol. 2012;67(6):1289–1295. https://doi.org/10.1016/j.jaad.2012.04.027

2. Lipsker D, Veran Y, Grunenberger F, et al. The Schnitzler Syndrome: Four New Cases and Review of the Literature. Med. 2001;80(1):37–44. https://doi.org/10.1097/00005792-200101000-00004

3. de Koning H, Bodar E, van Der Meer J, et al. Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment. Semin Arthritis Rheu. 2007;37(3):137–148. https://doi.org/10.1016/j.semarthrit.2007.04.001

4. Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: A French multicenter study. Autoimmun Rev. 2014;13(10):1035–1041. https://doi.org/10.1016/j.autrev.2014.08.031

5. Krause K, Feist E, Fiene M, et al. Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129(3):848–850. https://doi.org/10.1016/j.jaci.2011.10.031

6. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. https://doi.org/10.1111/all.13397

7. Rochet N, Chavan R, Cappel M, et al. Sweet syndrome: Clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557–564. https://doi.org/10.1016/j.jaad.2013.06.023

8. Lee H, Sinha A. Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmun. 2006;39(6):433–444. https://doi.org/10.1080/08916930600886851

9. Mehregan D, Hall M, Gibson L. Urticarial vasculitis: A histopathologic and clinical review of 72 cases. J Am Acad Dermatol. 1992;26(3):441–448. https://doi.org/10.1016/0190-9622(92)70069-R

10. Jachiet M, Flageul B, Deroux A, et al. The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-Seven Patients. Arthritis Rheum. 2015;67(2):527–534. https://doi.org/10.1002/art.38956

     

Acknowledgements

Author Profiles

Tayler D. Parker

UT McGovern Medical School

Ms. Parker is a 4th year medical student at UT McGovern Medical School. Her research interests include unique presentations of dermatologic conditions and quality improvement in the residency application process and graduate medical education curriculum. At McGovern, she is involved in the Medical Education Scholarly Concentration and serves as Vice President for the Gold Humanism Honor Society. She plans to apply for a residency in dermatology.

John R. Griffin

Kelsey-Seybold Clinic

Dr. John Griffin is the director of dermatopathology as well as a clinical dermatologist at the multispecialty Kelsey-Seybold Clinic. He earned his MD at UT Houston Medical School, now UT McGovern Medical School and completed his residency in dermatology at Mayo Clinic in Rochester, MN. Dr. Griffin completed a fellowship in dermatopathology at Ackerman Academy of Dermatopathology in New York City. In addition to his clinical practice Dr. Griffin is also on the editorial board for Cutis and is on the ASDP virtual slide committee.